Benzoporphyrin derivative data

QLTIF reported preliminary results of a Phase I/II trial with 61 patients with severe (wet) AMD, conducted with partner Ciba Vision Ophthalmics. BPD, a light-activated drug, selectively closed abnormal blood vessels in the eye following a single treatment without causing vision loss typical of current treatments.

Following treatment, all patients demonstrated partial or complete closure of the diseased blood vessels. Mean visual actuity remained stable over the three-month follow-up period. The data were presented at the Association for Research in Vision and Ophthalmology meeting in Ft. Lauderdale, Fla. ...